{
  "docId": "019de076-9434-73df-8e70-401e13bb3d65",
  "docSlug": "692690be0ea25b83b6a4c7490ff14999",
  "documentTitle": "BioAtla | Investor Presentation Deck | 55 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 55,
  "pageCount": 55,
  "prevPage": 54,
  "nextPage": null,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "Uses a Venn-like diagram to connect technology, pipeline, and financial status.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9434-73df-8e70-401e13bb3d65/55",
  "deckHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65",
  "deckJsonHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65.json",
  "deckAnchorHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65#slide-55",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.94,
        "x": 0.03,
        "y": 0.315
      },
      "kind": "diagram",
      "text": "Proprietary technology, Broad applicability in solid tumors, Increases therapeutic window, Two Phase 2 CAB-ADCs, one Phase 2 CAB-CTLA-4 and one Phase 1 dual CAB-bispecific T-cell engager, CAB-AXL-ADC (BA3011) advancing potentially registrational trial in sarcoma as well as potentially in other indications, Prioritized pipeline, Clinical readouts for multiple indications / assets through 2024, Advancing strategic collaboration discussions, $141.3 million in cash and cash equivalents as of 09/30/23, Cash position sufficient into 2H 2025",
      "attrs": null,
      "subkind": "venn",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5d744fe-d534-45b1-bea2-bf1967f69096",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "BioAtla is a clinical stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABs)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a667ec55-85aa-4fc4-b3db-5bd1e54ab9e8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "fb57f2ea-d751-4476-b371-5e2b2e1bf8c9",
      "evidence": "BioAtla is a clinical stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABs)",
      "confidence": 0.9
    },
    {
      "name": "Venn diagram",
      "slug": "venn-diagram",
      "agent": null,
      "layer": "slide",
      "matchId": "57b628f3-ba6a-4e4d-9003-d00c45336564",
      "evidence": "Proprietary technology, Broad applicability in solid tumors, Increases therapeutic window, Two Phase 2 CAB-ADCs, one Phase 2 CAB-CTLA-4 and one Phase 1 dual CAB-bispecific T-cell engager, CAB-AXL-ADC (BA301",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 55,
      "from": 54,
      "beatId": "354d245d-5f7e-45fe-bdc1-930eff0f5f3d",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Why Now",
      "beatSlug": "sequoia-pitch-why-now",
      "evidence": "The 'why now' section is implicit, with a focus on near-term value and upcoming milestones on pages 54-55.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}